Frazier Life Sciences Management L.P. Cuts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Frazier Life Sciences Management L.P. trimmed its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 12.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 731,020 shares of the company's stock after selling 101,200 shares during the quarter. Frazier Life Sciences Management L.P. owned approximately 1.44% of Tyra Biosciences worth $17,186,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TYRA. Vanguard Group Inc. boosted its stake in Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock worth $14,757,000 after purchasing an additional 140,833 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company's stock valued at $929,000 after acquiring an additional 14,352 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company's stock valued at $377,000 after acquiring an additional 2,574 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock valued at $2,723,000 after acquiring an additional 145,346 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new position in shares of Tyra Biosciences during the 2nd quarter valued at approximately $3,047,000. 84.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TYRA shares. Bank of America upgraded Tyra Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Oppenheimer increased their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research report on Thursday, September 19th. Wedbush reiterated an "outperform" rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. HC Wainwright lowered their price target on Tyra Biosciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Monday, November 11th. Finally, Piper Sandler assumed coverage on Tyra Biosciences in a research report on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $31.00.

Tyra Biosciences Stock Up 1.4 %

TYRA traded up $0.23 during trading on Tuesday, reaching $16.23. The company had a trading volume of 147,714 shares, compared to its average volume of 195,704. The stock has a market cap of $821.29 million, a P/E ratio of -10.08 and a beta of 1.01. The business has a 50 day simple moving average of $19.01 and a 200-day simple moving average of $19.70. Tyra Biosciences, Inc. has a 52 week low of $11.24 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01). As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total value of $179,131.26. Following the sale, the director now owns 472,207 shares in the company, valued at $7,635,587.19. This trade represents a 2.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Alan Fuhrman purchased 9,500 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the purchase, the chief financial officer now owns 12,849 shares of the company's stock, valued at approximately $205,584. This trade represents a 283.67 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 101,050 shares of company stock worth $2,235,492 over the last quarter. Company insiders own 15.40% of the company's stock.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.